Skip to main content
Multiple Myeloma
Patient-Reported Outcomes of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone
Read More
Multiple Myeloma
Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma with No Prior BCMA-Targeted Treatment: Results from MagnetisMM-3
Read More
Multiple Myeloma
ALLO-715, an Allogeneic Anti-BCMA CAR T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: Results from UNIVERSAL
Read More
Multiple Myeloma
2022 Year in Review: Multiple Myeloma Introduction
Read More
Multiple Myeloma
First-in-Human Phase 1/2 Study of REGN5458 in Heavily Pretreated Patients with Multiple Myeloma
Read More
Multiple Myeloma
Real-World Analysis of Treatment Patterns and Outcomes in Patients with MM by Cytogenetic Risk
Read More
Multiple Myeloma
Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1/2 Results from MonumenTAL-1
Read More
Multiple Myeloma
Systematic Review and Meta-Analysis Comparing Whole-Body MRI and FDG PET/CT in Evaluating Treatment Response in Multiple Myeloma
Read More
Multiple Myeloma
Isatuximab plus Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: ICARIA-MM Final OS Analysis
Read More
Multiple Myeloma
Daratumumab plus Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: Long-Term Outcomes from MAIA
Read More
Page 2 of 3
Results 11 - 20 of 25